2Y03
TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND AGONIST ISOPRENALINE
2Y03 の概要
| エントリーDOI | 10.2210/pdb2y03/pdb |
| 関連するPDBエントリー | 1DEP 2VT4 2Y00 2Y01 2Y02 2Y04 |
| 分子名称 | BETA-1 ADRENERGIC RECEPTOR, CHOLESTEROL HEMISUCCINATE, HEGA-10, ... (6 entities in total) |
| 機能のキーワード | receptor, g protein coupled receptor, seven-helix receptor, integral membrane protein, thermostabilising point mutations, gpcr, 7tm receptor |
| 由来する生物種 | MELEAGRIS GALLOPAVO (TURKEY) |
| タンパク質・核酸の鎖数 | 2 |
| 化学式量合計 | 75577.45 |
| 構造登録者 | Warne, A.,Moukhametzianov, R.,Baker, J.G.,Nehme, R.,Edwards, P.C.,Leslie, A.G.W.,Schertler, G.F.X.,Tate, C.G. (登録日: 2010-11-30, 公開日: 2011-01-12, 最終更新日: 2024-11-13) |
| 主引用文献 | Warne, A.,Moukhametzianov, R.,Baker, J.G.,Nehme, R.,Edwards, P.C.,Leslie, A.G.W.,Schertler, G.F.X.,Tate, C.G. The Structural Basis for Agonist and Partial Agonist Action on a Beta1-Adrenergic Receptor Nature, 469:241-, 2011 Cited by PubMed Abstract: β-adrenergic receptors (βARs) are G-protein-coupled receptors (GPCRs) that activate intracellular G proteins upon binding catecholamine agonist ligands such as adrenaline and noradrenaline. Synthetic ligands have been developed that either activate or inhibit βARs for the treatment of asthma, hypertension or cardiac dysfunction. These ligands are classified as either full agonists, partial agonists or antagonists, depending on whether the cellular response is similar to that of the native ligand, reduced or inhibited, respectively. However, the structural basis for these different ligand efficacies is unknown. Here we present four crystal structures of the thermostabilized turkey (Meleagris gallopavo) β(1)-adrenergic receptor (β(1)AR-m23) bound to the full agonists carmoterol and isoprenaline and the partial agonists salbutamol and dobutamine. In each case, agonist binding induces a 1 Å contraction of the catecholamine-binding pocket relative to the antagonist bound receptor. Full agonists can form hydrogen bonds with two conserved serine residues in transmembrane helix 5 (Ser(5.42) and Ser(5.46)), but partial agonists only interact with Ser(5.42) (superscripts refer to Ballesteros-Weinstein numbering). The structures provide an understanding of the pharmacological differences between different ligand classes, illuminating how GPCRs function and providing a solid foundation for the structure-based design of novel ligands with predictable efficacies. PubMed: 21228877DOI: 10.1038/NATURE09746 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2.85 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






